Literature DB >> 10799575

Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1.

S Lee1, C K Lapham, H Chen, L King, J Manischewitz, T Romantseva, H Mostowski, T S Stantchev, C C Broder, H Golding.   

Abstract

The chemokine receptors CCR5 and CXCR4 were found to function in vivo as the principal coreceptors for M-tropic and T-tropic human immunodeficiency virus (HIV) strains, respectively. Since many primary cells express multiple chemokine receptors, it was important to determine if the efficiency of virus-cell fusion is influenced not only by the presence of the appropriate coreceptor (CXCR4 or CCR5) but also by the levels of other coreceptors expressed by the same target cells. We found that in cells with low to medium surface CD4 density, coexpression of CCR5 and CXCR4 resulted in a significant reduction in the fusion with CXCR4 domain (X4) envelope-expressing cells and in their susceptibility to infection with X4 viruses. The inhibition could be reversed either by increasing the density of surface CD4 or by antibodies against the N terminus and second extracellular domains of CCR5. In addition, treatment of macrophages with a combination of anti-CCR5 antibodies or beta-chemokines increased their fusion with X4 envelope-expressing cells. Conversely, overexpression of CXCR4 compared with CCR5 inhibited CCR5-dependent HIV-dependent fusion in 3T3.CD4.401 cells. Thus, coreceptor competition for association with CD4 may occur in vivo and is likely to have important implications for the course of HIV type 1 infection, as well as for the outcome of coreceptor-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799575      PMCID: PMC110853          DOI: 10.1128/jvi.74.11.5016-5023.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5.

Authors:  C K Lapham; M B Zaitseva; S Lee; T Romanstseva; H Golding
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

2.  Increased association of glycoprotein 120-CD4 with HIV type 1 coreceptors in the presence of complex-enhanced anti-CD4 monoclonal antibodies.

Authors:  H Golding; J Ouyang; M Zaitseva; C C Broder; D S Dimitrov; C Lapham
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-20       Impact factor: 2.205

3.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

4.  CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus.

Authors:  S G Kitchen; J A Zack
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

5.  Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1.

Authors:  M Moriuchi; H Moriuchi; W Turner; A S Fauci
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

6.  CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.

Authors:  M B Zaitseva; S Lee; R L Rabin; H L Tiffany; J M Farber; K W Peden; P M Murphy; H Golding
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

7.  Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level.

Authors:  L Pedroza-Martins; K B Gurney; B E Torbett; C H Uittenbogaart
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  Cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells.

Authors:  J P Zoeteweij; H Golding; H Mostowski; A Blauvelt
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

9.  CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation.

Authors:  R D Berkowitz; K P Beckerman; T J Schall; J M McCune
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

10.  Interferon-gamma upregulates CCR5 expression in cord and adult blood mononuclear phagocytes.

Authors:  D Hariharan; S D Douglas; B Lee; J P Lai; D E Campbell; W Z Ho
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

View more
  14 in total

Review 1.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120IIIB binding to the cell surface.

Authors:  Laura Martínez-Muñoz; Rubén Barroso; Sunniva Y Dyrhaug; Gemma Navarro; Pilar Lucas; Silvia F Soriano; Beatriz Vega; Coloma Costas; M Ángeles Muñoz-Fernández; César Santiago; José Miguel Rodríguez Frade; Rafael Franco; Mario Mellado
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

3.  Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion.

Authors:  Janet E Lineberger; Renee Danzeisen; Daria J Hazuda; Adam J Simon; Michael D Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.

Authors:  K Salzwedel; E A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture.

Authors:  Jadwiga Nitkiewicz; Wei Chao; Galina Bentsman; Jinliang Li; Seon-Young Kim; So Young Choi; Gabrielle Grunig; Harris Gelbard; Mary Jane Potash; David J Volsky
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

6.  Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Authors:  A Trkola; T J Ketas; K A Nagashima; L Zhao; T Cilliers; L Morris; J P Moore; P J Maddon; W C Olson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.

Authors:  Javier Garcia-Perez; Patricia Rueda; Isabelle Staropoli; Esther Kellenberger; Jose Alcami; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

8.  A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients.

Authors:  A Vasilescu; Y Terashima; M Enomoto; S Heath; V Poonpiriya; H Gatanaga; H Do; G Diop; T Hirtzig; P Auewarakul; D Lauhakirti; T Sura; P Charneau; S Marullo; A Therwath; S Oka; S Kanegasaki; M Lathrop; K Matsushima; J-F Zagury; F Matsuda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

9.  Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection.

Authors:  Yanjie Yi; Lamorris Loftin; Lingshu Wang; Sarah J Ratcliffe; Jesse Isaacman-Beck; Ronald G Collman
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

10.  Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson; Ruy M Ribeiro; Leor S Weinberger
Journal:  PLoS Comput Biol       Date:  2009-08-14       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.